DE69516166T2 - Selbstmordgene und hybride aus nukleotid oder pyrimidin-nukleosid-analogen mit selbstmordgene für die gentherapie - Google Patents

Selbstmordgene und hybride aus nukleotid oder pyrimidin-nukleosid-analogen mit selbstmordgene für die gentherapie

Info

Publication number
DE69516166T2
DE69516166T2 DE69516166T DE69516166T DE69516166T2 DE 69516166 T2 DE69516166 T2 DE 69516166T2 DE 69516166 T DE69516166 T DE 69516166T DE 69516166 T DE69516166 T DE 69516166T DE 69516166 T2 DE69516166 T2 DE 69516166T2
Authority
DE
Germany
Prior art keywords
suicide genes
pyrimidine
nucleotide
gene therapy
nucleoside analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69516166T
Other languages
English (en)
Other versions
DE69516166D1 (de
Inventor
Gerard Tiraby
Jean-Paul Reynes
Michele Tiraby
Christophe Cazaux
Daniel Drocourt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAYLA TOULOUSE
Original Assignee
CAYLA TOULOUSE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CAYLA TOULOUSE filed Critical CAYLA TOULOUSE
Publication of DE69516166D1 publication Critical patent/DE69516166D1/de
Application granted granted Critical
Publication of DE69516166T2 publication Critical patent/DE69516166T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02009—Uracil phosphoribosyltransferase (2.4.2.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • C12Y207/04009—Phosphotransferases with a phosphate group as acceptor (2.7.4) dTMP kinase (2.7.4.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69516166T 1994-11-17 1995-11-16 Selbstmordgene und hybride aus nukleotid oder pyrimidin-nukleosid-analogen mit selbstmordgene für die gentherapie Expired - Lifetime DE69516166T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/343,923 US5856153A (en) 1994-11-17 1994-11-17 Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
PCT/FR1995/001511 WO1996016183A1 (fr) 1994-11-17 1995-11-16 Genes suicide et associations d'analogues de nucleobases et nucleosides pyrimidiques avec des genes suicide en vue d'une therapie genique

Publications (2)

Publication Number Publication Date
DE69516166D1 DE69516166D1 (de) 2000-05-11
DE69516166T2 true DE69516166T2 (de) 2000-11-16

Family

ID=23348272

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69516166T Expired - Lifetime DE69516166T2 (de) 1994-11-17 1995-11-16 Selbstmordgene und hybride aus nukleotid oder pyrimidin-nukleosid-analogen mit selbstmordgene für die gentherapie

Country Status (6)

Country Link
US (1) US5856153A (de)
EP (1) EP0792369B1 (de)
AU (1) AU4180996A (de)
DE (1) DE69516166T2 (de)
ES (1) ES2146788T3 (de)
WO (1) WO1996016183A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
FR2746016B1 (fr) 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
US8716558B2 (en) 1999-06-30 2014-05-06 Marker Gene Technologies, Inc. Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase
US6656917B1 (en) 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
DE19947668A1 (de) * 1999-10-04 2001-04-19 Univ Eberhard Karls Tumorspezifischer Vektor für die Gentherapie
US20030214690A1 (en) * 2001-11-26 2003-11-20 Escuti Michael J. Holographic polymer photonic crystal
JP4651942B2 (ja) 2001-12-20 2011-03-16 フアーマセツト・インコーポレイテッド Ｅｂｖ及びｋｈｓｖ感染並びにそれに伴う異常細胞増殖の治療
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2003219057A1 (en) 2002-03-15 2003-09-29 Baxter Healthcare S.A. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US7127023B2 (en) * 2002-05-21 2006-10-24 Duke University Batch target and method for producing radionuclide
GB2390606A (en) * 2002-06-21 2004-01-14 Mohammad Saeid Hejazi Expression Plasmid
PT1649023E (pt) 2003-07-21 2008-11-20 Transgene Sa Polipéptido com actividade de citosina desaminase melhorada
KR101134185B1 (ko) * 2004-11-08 2012-04-09 트랜스진 에스.에이. 포유동물에서 항종양 또는 항바이러스 치료를 이행하기위해 고안된 부분품들의 키트
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
US10113150B2 (en) 2011-06-06 2018-10-30 Invivosciences, Inc. Engineered cardiac tissues and methods of using them
JP6657115B2 (ja) 2014-04-10 2020-03-04 トランジェーヌＴｒａｎｓｇｅｎｅ ポックスウイルス腫瘍細胞崩壊性ベクター
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN114729324A (zh) 2019-07-24 2022-07-08 斯比根公司 永生化干细胞株的制备方法及其用途
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2569723B1 (fr) * 1984-08-31 1986-09-19 Centre Nat Rech Scient Application des antibiotiques de la famille des phleomycines a titre d'agent de selection dans le domaine du genie genetique
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies

Also Published As

Publication number Publication date
DE69516166D1 (de) 2000-05-11
EP0792369B1 (de) 2000-04-05
WO1996016183A1 (fr) 1996-05-30
AU4180996A (en) 1996-06-17
US5856153A (en) 1999-01-05
ES2146788T3 (es) 2000-08-16
EP0792369A1 (de) 1997-09-03

Similar Documents

Publication Publication Date Title
DE69516166T2 (de) Selbstmordgene und hybride aus nukleotid oder pyrimidin-nukleosid-analogen mit selbstmordgene für die gentherapie
EP0754242A4 (de) SYNTHESE UND SUBSTANZ, HYBRIDISIERUNG UND NUKLEASEFESTE EIGENSCHAFTEN DES OLIGONUKLEOTID-N3'-m(7)P5'-PHOSPHORAMIDATS
HUP9802445A3 (en) Liposomal oligonucleotide compositions and process for inhibiting the human raf
ATE392475T1 (de) Elongase gene und ihre verwendung
PL335226A1 (en) Gene sequencer and related methods
HK1034999A1 (en) Dsrna-mediated regulation of gene expression in plants.
ZA955210B (en) Inducible nitric oxide synthase gene for treatment of disease
HUP0003384A3 (en) Product comprising at least a double stranded rna combined with at least an antiviral agent
EP0970251A4 (de) Analyse genetischer polymorphismen und genkopienzahl
PL343599A1 (en) Genes controlling diseases
BR9401355A (pt) Oligonucleotídeo e nucleotídeo.
EP1107797A4 (de) Hypoxie-regulierte gene.
HUP0104221A3 (en) Dna comprising rice anther-specific gene and transgenic plant transformed therewith
PL344391A1 (en) Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
EP0791061A4 (de) Tiere mit gezielter genunterbrechung
HUP0100044A3 (en) Modified antisense nucleotides complementary to a section of the human ha-ras gene
DE3678702D1 (de) Antitumorprotein-gen von streptococcus pyogenes su, plasmide, die das gen enthalten, transformantenzellen, die die plasmide beherbergen, und verfahren zur herstellung des antitumorproteins.
IL118305A0 (en) Ataxia-telangiectasia gene and its genomic organization
GB9817278D0 (en) Plant resistance genes
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
DE19983297T1 (de) Gene, die für beta-Agarasen kodieren, und ihre Verwendung zur Herstellung von Enzymen für den biologischen Abbau von Agar
AU5052599A (en) Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases
HUP0001909A3 (en) Plant gene constructs and their use
ZA9810533B (en) Targeted manipulation of genes in plants
AU3068099A (en) Chromosome 11-linked coronary heart disease susceptibility gene chd1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition